-
Inventory: A selection of BMJ studies on August 22, 2020.
Time of Update: 2020-09-23
The increased risk of maternal mortality due to premature birth: https://doi.org/10.1136/bmj.m2533 Researchers recently examined the long-term risk of premature death associated with pregnant women in a population-based queue of women.
-
Lancet oncol: Circulatory tumor DNA analysis is enough to guide breast cancer targeted treatment!
Time of Update: 2020-09-23
study aims to assess the accuracy of ctDNA testing in assessing advanced breast cancer and the ability of ctDNA testing to screen patients suitable for mutation-targeted treatment.
requires patients to have received at least one treatment for advanced breast cancer or to relapse within 12 months of new assisted/assisted chemotherapy.
-
NEJM:Tepotinib treated met exon 14 jump mutation non-small cell lung cancer phase II clinical effect was significant.
Time of Update: 2020-09-23
study, tepotinib treatment response rate was about 50% for patients with advanced non-small cell lung cancer with met exon 14 jump mutation, and the most common adverse events above level 3 were exostular edema.
-
Cell Death Dis:miR-210-3p regulates the glycolysis in triple-negative breast cancer.
Time of Update: 2020-09-23
different from other breast cancer subtypes, TNBC showed high metabolic reprogramming, strong aggressiveness and lack of targeted treatment.
, the study identified miRNAs that regulate aerobic enzymes and revealed that miR-210-3p had an important contribution to TNBC's Warburg effect.
-
Lancet oncol: The efficacy of the PARP inhibitor veliparib in the treatment of advanced breast cancer with BRCA mutations.
Time of Update: 2020-09-23
in the BROCADE3 trial, the researchers compared the efficacy of veliparib and placebo combined carbotin and yew alcohol treatment for her2-negative advanced breast cancer patients with BRCA1 or BRCA2 embryonic mutations.
-
Eur Radiol: Preoperative precision and non-invasive identification of ovarian cancer subsectives.
Time of Update: 2020-09-23
Recently, Gao Xin team of Suzhou Institute of Biomedical Engineering Technology of Chinese Academy of Sciences, in collaboration with Qiang Jinwei team of Jinshan Hospital affiliated with Fudan University, jointly carried out the first large sample study of ovarian cancer based on MRI imaging histology, based on the non-invasive identification machine learning model of type I and type II ovarian cancer, and used visualization technology to identify key areas for the first time in imaging.
-
Nat Commun: CNS Tumor Immunology Microeconviral Analysis Reveals Anti-Tumor Immunity Correlation.
Time of Update: 2020-09-23
Immunotherapy is an attractive alternative cancer strategy compared to traditional surgery, chemotherapy and radiotherapy, and is particularly suitable for targeting diffuse invasive growth tumors such as central nervous system (CNS) tumors.
of tumor immune micro-environment (TIME) is a key determinant of tumor-immune interaction.
-
Stop sunbathing! Skin cancer deaths have soared by 70% since 1970
Time of Update: 2020-09-23
Melanoma-related deaths have soared 2.5 times in the UK since 1970, according to Cancer Research UK.
in the UK, 91 per cent of melanoma patients are diagnosed at an early stage, and 91 per cent survive for five years or more.
-
AJOG: CD70 Antibody-Drug Coupler is expected to be a target drug for uterine smooth muscoma.
Time of Update: 2020-09-23
researchers first screened target membrane proteins by comparing the expression of membrane proteins in three uterine smooth muscular tumor cell lines (SK-UT-1, SK-LMS-1 and SKN) and normal uterine myoblasts.
-
Nat Commun: HIF-1 alpha and HIF-2 alpha play the opposite regulatory role in renal transparent cell carcinoma.
Time of Update: 2020-09-23
Although studies on ccRCC have shown that HIF-1 alpha is an inhibitor of invasive tumor behavior and HIF-2 alpha has a promoting effect, it is not clear what role the two play in tumor development.
-
Cell Death Dis:BRD9 activates the TUFT1/AKT path pathfectal path to promote the growth and metastasis of hepatocellular carcinoma.
Time of Update: 2020-09-23
all, the study showed that BRD9 can promote the growth and metastasis of liver cancer cells by activating the TUFT1/AKT pathrapy, which may be a potential biomarker and therapeutic target for HCC.
-
Molecular Cell: DNA damage promotes the degradation of TMPRSS2-ERG cancer proteins and inhibits prostate cancer progression.
Time of Update: 2020-09-23
the elimination of the cancer-related gene PTEN or infergic GSK3 beta eliminates the degradation of TMPRSS2-ERG induced by DNA damage.
blocking the DNA damage-induced degradation process of TMPRSS2-ERG cancer proteins in fusion protein-positive PCa cells and mouse models can cause tumor cells to develop chemotherapy resistance.
-
Gan Li Pharmaceutical CDK4/6 inhibitors are eligible for FDA orphan drugs to treat malignant gliomas.
Time of Update: 2020-09-23
On September 10, Gan Li Pharmaceuticals announced that the FDA has granted its cell cycle protein-dependent kinase 4/6 (CDK4/6) inhibitor GLR2007 orphan drug eligibility for the treatment of malignant gliomas, including glioblastoma (GBM).
-
J clin oncol: Pacopani vs amycin for the treatment of advanced soft tissue sarcoma in elderly patients.
Time of Update: 2020-09-23
compared to the amycin group, the PFS in the Paropani group was non-shoddy (HR 1.0, 95% CI 0.65-1.53), and the rates of stage 4 neotromycin reduction and fever neotromycin reduction were lower than in the amycin group.
-
Cell Death Differ: TRIM22 activates the NF-B signal by accelerating I-B alpha degradation.
Time of Update: 2020-09-23
trim protein family, a sub-family of RENING-type E3 ubiquitin connective enzymes, can act as a key regulatory factor in the development of a variety of cancers, including GBM, by regulating the transcriptional activity of NF-B.
-
Br J Cancer: Lack of oxygen can increase the rate of evolution of glioblastoma.
Time of Update: 2020-09-23
that low oxygen conditions may be effective in affecting the rate of tumor evolution, increasing the likelihood of key mutations.
-
Clin Cancer Res: Targeting extracellular substate reconstruction restores BRAFi-resistant melanoma's sensitivity to BRAF inhibitors.
Time of Update: 2020-09-23
in this study, Marusak and others studied the role of ECM reconstruction in braf mutation melanoma resistance to BRAF inhibitor therapy through collagenase MT1-MMP.
MT1-MMP inhibition, mediated by shRNA or ND322, in collaboration with BRAFi can lead to resensitivity of drug-resistant cells and tumors to BRAFi.
-
Acta Neuropathologica: CdKN2A deficiency in on-screen membrane chamber spacing tumors with RELA changes is a sign of poor prognosis: a retrospective analysis of HIT chamber spacer tumor trials.
Time of Update: 2020-09-23
9 out of 54 cases (16.7%) detected CDKN2A purity deficiency (total loss) (Figure 1c); in one case, few tumor cells expressed the p16 protein, indicating that the CDKN2A alletic gene was retained in a single cell.
-
NEJM: Nubeqa (darolutamide) significantly extends the lifespan of patients with non-metastatic prostate cancer!
Time of Update: 2020-09-23
Karim Fizazi, head of research at ARAMIS, said: "Through ongoing research, we have identified treatments that focus on extending life expectancy and reducing side effects in men with nmCRPC." men who received drarolutamide combined androgen deprivation therapy (ADT) showed significant improvement in OS compared to placebo combined ADT, and a 31% lower risk of death (HR s 0.69, 95% CI 0.53-0.88, p s 0.003).
-
NEJM: Selpercatinib is used in the treatment of PATIENTs with RET fusion-positive non-small cell lung cancer.
Time of Update: 2020-09-23
105 patients with RET fusion-positive non-small cell lung cancer who had previously underwent platinum chemotherapy, the objective response rate of Selpercatinib treatment was 64%.
